Physician profile
Mark K Li
NPI 1356338032
$17,046.75
in general payments reported to CMS, 2019-2025
13 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,187 · 2021: $164 · 2022: $651 · 2023: $566 · 2024: $658 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15,192.83 | 2019-2025 | Vemlidy, Livdelzi |
| Bayer Healthcare Pharmaceuticals INC. | $458.26 | 2022-2025 | |
| Novo Nordisk INC | $421.81 | 2019-2020 | |
| Glaxosmithkline, LLC. | $218.23 | 2023-2024 | Shingrix, Arexvy |
| Amgen INC. | $172.10 | 2019-2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $136.61 | 2020 | |
| Merck Sharp & Dohme LLC | $111.54 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $100.00 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.80 | 2019 | |
| Lilly USA, LLC | $71.25 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Abbott Laboratories | $36.00 | 2019-2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $18.86 | 2024 | |
| Pfizer INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.